Richter agrees AUD 604m takeover of Mayne Pharma at near-100% premium
Gedeon Richter will pay cash for the ASX-listed company, adding its US women's health and dermatology products, subject to a sale of Mayne's International arm to Evaris Pharma.
Gedeon Richter has agreed to buy Mayne Pharma outright for AUD 6.40 a share in cash, a price that values the ASX-listed company at about AUD 604 million. The companies announced the agreement on 16 November 2026. The offer is roughly 99% above Mayne's last closing price, so shareholders are being offered close to double the prior market value.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.